A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC)
2016 ◽
Vol 27
◽
pp. vi452
◽
L.V. Sequist
◽
I. Anderson
◽
T.M. Bauer
◽
N. Demars
◽
E. Felip
◽
...
J. Liang
◽
W. Wang
◽
G. Ou
◽
Z. Hui
◽
J. Lv
◽
...
K. Tanaka
◽
I. Okamoto
◽
N. Yamamoto
◽
Y. Hattori
◽
N. Masuda
◽
...
1990 ◽
Vol 6
(1-2)
◽
pp. 62
2016 ◽
Vol 34
(15_suppl)
◽
pp. TPS9110-TPS9110
◽
Lecia V. Sequist
◽
Ian Churchill Anderson
◽
Nathan Demars
◽
Enriqueta Felip
◽
Wael A. Harb
◽
...
Sam Janes
◽
Laura Succony
2021 ◽
Vol 16
(3)
◽
pp. S651-S652
J. Beal
◽
D. Gomes
◽
P. Taranto
◽
L. Koch
◽
A.C. Rezende
◽
...
Ying Cheng
◽
Qiming Wang
◽
Kai Li
◽
Jianhua Shi
◽
Ying Liu
◽
...
2019 ◽
Vol 14
(10)
◽
pp. S646
◽
C. Ocampo
◽
J. Wu
◽
J. Dey
◽
Z. Sun
◽
M. Motwani
◽
...
2012 ◽
Vol 76
(1)
◽
pp. 78-83
◽
Benjamin Besse
◽
David Planchard
◽
Anne-Sophie Veillard
◽
Laurent Taillade
◽
David Khayat
◽
...
Close
Export Citation Format
Close
Share Document
Close